Pulmonx (NASDAQ:LUNG) Earns “Buy” Rating from D. Boral Capital

Pulmonx (NASDAQ:LUNG)‘s stock had its “buy” rating reissued by research analysts at D. Boral Capital in a research note issued on Friday,Benzinga reports. They currently have a $14.00 price objective on the stock.

Several other equities research analysts have also recently commented on LUNG. Wall Street Zen upgraded Pulmonx from a “sell” rating to a “hold” rating in a research note on Sunday, November 16th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Pulmonx in a report on Thursday, January 22nd. Finally, Lake Street Capital cut their price objective on shares of Pulmonx from $8.00 to $4.00 and set a “buy” rating on the stock in a research report on Tuesday, October 28th. Five equities research analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Hold” and an average target price of $6.81.

Pulmonx Price Performance

LUNG stock opened at $1.51 on Friday. The stock has a 50-day moving average price of $1.92 and a two-hundred day moving average price of $1.79. Pulmonx has a 1 year low of $1.31 and a 1 year high of $9.35. The stock has a market cap of $62.08 million, a PE ratio of -1.07 and a beta of 0.07. The company has a current ratio of 4.86, a quick ratio of 4.15 and a debt-to-equity ratio of 0.62.

Institutional Trading of Pulmonx

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Corton Capital Inc. acquired a new position in shares of Pulmonx during the 2nd quarter worth about $32,000. Cerity Partners LLC bought a new stake in Pulmonx in the fourth quarter valued at approximately $27,000. Opal Capital LLC acquired a new stake in shares of Pulmonx in the fourth quarter valued at approximately $29,000. Regatta Capital Group LLC acquired a new stake in shares of Pulmonx in the fourth quarter valued at approximately $30,000. Finally, Lazard Asset Management LLC bought a new position in shares of Pulmonx during the 4th quarter worth approximately $31,000. 91.04% of the stock is owned by institutional investors.

About Pulmonx

Pulmonx Corporation is a commercial-stage medical device company focused on bronchoscopic lung volume reduction for patients suffering from severe emphysema. The company’s flagship therapy, the Zephyr® Endobronchial Valve System, employs one-way valves delivered via a minimally invasive bronchoscopic procedure to collapse diseased portions of the lung, reducing hyperinflation and improving respiratory function. Complementing this treatment, Pulmonx offers the Chartis® Pulmonary Assessment System, which provides clinicians with quantitative measurements of collateral ventilation to aid in patient selection and optimize clinical outcomes.

The Zephyr Valve received the CE mark in Europe in 2008 and FDA approval in the United States in 2018, and it has since been adopted by leading respiratory and thoracic centers across North America and Europe.